yellow fever is a dreadful disease with a long history, but fortunately is vaccine preventable, unlike many viral diseases (ebola, lassa fever, etc). however, there are problems with yellow fever vaccination which were recently described in an article about fractional-dose vaccination in the new england journal of medicine. in 2016, a shortage of millions of doses of yellow fever vaccine occurred, because of yellow fever outbreaks in angola and the democratic republic of congo. the world health organization urgently needed a solution, and fractionating the available yellow fever vaccine doses and administering a reduced volume of vaccine was one proposal. use of fractional-dose vaccination in mass vaccination campaigns presented an opportunity to compare the safety of fractional-dose and full-dose yellow fever vaccines — particularly rates of rare, serious adverse events. in the perspective article, the authors argued that “continued dialogue and coordination among the policy, research, and funding communities are critical to ensure that when public health emergencies arise, there is sufficient evidence to make robust policy decisions quickly. policy-driven research agendas are important tools for facilitating such coordination.”
what do you think about the the yellow fever vaccination shortage? is the fractional approach the right way to go?
please leave a reply below if you like.
best regards, dr. phil lederer